DRG Market Assessment reports

The rapid growth of digital therapeutic (DTx) solutions to treat medical problems, fueled by increased demand for telehealth services amid the COVID-19 pandemic, has tasked U.S. payers and pharmacy…

Triptans have long been the mainstay of acute treatment of migraine; however, in 2020, three novel oral nontriptan brands—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s…

Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…

Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of scleroderma (systemic sclerosis) comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide…

Clarivate Epidemiology’s coverage of scleroderma (systemic sclerosis) comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide…